HLX14, a denosumab biosimilar targeted for the treatment of postmenopausal osteoporosis in patients with a high risk of fractures, was approved by China’s National Medical Products Administration (NMPA).
Shanghai Henlius Biotech said its denosumab biosimilar (HLX14) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. The approval came just 2 months after the investigational new drug application for HLX14 was accepted for review by the NMPA.
Osteoporosis affects almost 70 million Chinese over the age of 50 and is responsible for 687,000 hip fractures each year, according to the International Osteoporosis Foundation. . A large number of cases are concentrated in postmenopausal women and elderly patients. Osteoporosis can lead to a higher risk of fractures, which can greatly affect a patient’s quality of life.
“At present, the rate of medical consultation and standardized treatment of osteoporosis is still low globally,” and the continual growth of the patient population constitutes an urgent need for treatment options, Henlius officials said in a statement.
Henlius followed biosimilar guidance issued by China and the European Medicines Agency (EMA) to complete head-to-head studies analyzing comparative pharmacology, pharmacokinetics, and biosimilarity between HLX14 and reference denosumab (Prolia).
Denosumab is a recombinant anti-RANKL human monoclonal antibody (mAb) injection that blocks the binding of RANKL receptors that regulate bone resorption, which in osteoporosis exceeds the rate of bone formation. Denosumab retards bone resorption, thereby favoring bone formation over bone resorption, leading to increased bone mass and a reduced risk of fractures.
Recently, Henlius announced that its bevacizumab biosimilar (HLX04) met primary end points in a phase 3 trial comparing the safety, efficacy, and immunogenicity compared with the reference product (Avastin).
Growing Osteoporosis Drug Market
In May, Daewon Pharmaceutical of Republic of Korea launched its teriparatide biosimilar, Terrosa, also for the treatment of osteoporosis in men and postmenopausal women with a high risk of fractures. Terrosa was the first teriparatide biosimilar launched in the Republic of Korea and the first biosimilar for Daewon.
Terrosa was approved by the EMA in 2017 and launched in that market in 2019. It is also available in the United States but not as a biosimilar.
Pfenex also has an approved teriparatide molecule that serves as a follow-on product to reference teriparatide Forsteo. In the United States, the company submitted a 505(b)(2) application for approval rather than an abbreviated Biologics License Application.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.